Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

In recent years, targeted therapies have proven beneficial in terms of progression-free survival (PFS) and overall survival (OS) in the treatment of metastatic renal cell carcinoma (mRCC). The tyrosine kinase inhibitors (TKIs) sorafenib and sunitinib are included in international clinical guidelines...

Full description

Bibliographic Details
Main Authors:	Caroline Randrup Hansen, Daniela Grimm, Johann Bauer, Markus Wehland, Nils E. Magnusson
Format:	Article
Language:	English
Published:	MDPI AG 2017-02-01
Series:	International Journal of Molecular Sciences
Subjects:	metastatic renal cell carcinoma sunitinib sorafenib hypertension tyrosine kinase inhibitors vascular endothelial growth factor
Online Access:	http://www.mdpi.com/1422-0067/18/2/461

Similar Items

THE SIDE EFFECTS OF SORAFENIB, SUNITINIB, AND TEMSIROLIMUS AND THEIR THERAPY IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA
by: N. Bhojani, et al.
Published: (2014-08-01)

THE SIDE EFFECTS OF SORAFENIB, SUNITINIB, AND TEMSIROLIMUS AND THEIR THERAPY IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA
by: N. Bhojani, et al.
Published: (2014-08-01)

Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma
by: Wen Cai, et al.
Published: (2017-08-01)

Use of sunitinib in patients with metastatic kidney cancer in real clinical practice
by: B. Ya. Alekseev, et al.
Published: (2016-05-01)

Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment
by: Nanna Bæk Møller, et al.
Published: (2019-09-01)

The effect of sunitinib on neuroblastoma and glioblastoma cell growth
by: Roos, Kelly
Published: (2021)

Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study
by: Ana Elena Martín-Aguilar, et al.
Published: (2021-01-01)

The Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-Kinase Inhibitors
by: Ole Vincent Ancker, et al.
Published: (2017-03-01)

Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence
by: Denian Wang, et al.
Published: (2020-09-01)

When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report
by: Yassir Sbitti, et al.
Published: (2018-03-01)

Treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue sarcoma: a pooled analysis
by: Que Y, et al.
Published: (2018-07-01)

Safety and efficacy of sunitinib in patients from Latin America: subanalysis of an expanded access trial in metastatic renal cell carcinoma
by: Barrios CH, et al.
Published: (2016-09-01)

The effect of apatinib in the treatment of metastatic renal cell carcinoma: a case report and review of the literature
by: Bi J, et al.
Published: (2017-07-01)

Sunitinib-Induced Acute Liver Failure
by: Anum Aqsa, et al.
Published: (2021-01-01)

Comparative Efficacy, Safety, and Costs of Sorafenib vs. Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
by: Huan Deng, et al.
Published: (2019-06-01)

Sorafenib is the first targeted agent to treat metastatic kidney cancer
by: V. B. Matveev, et al.
Published: (2015-03-01)

Sorafenib is the first targeted agent to treat metastatic kidney cancer
by: V. B. Matveev, et al.
Published: (2015-03-01)

Acute acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib
by: Leonardo Gomes da Fonseca, et al.
Published: (2014-04-01)

TARGET THERAPY IN PATIENTS OF LIVER METASTATIC CANCER PATIENTS IN REAL CLINICAL PRACTICE
by: B. Y. ALEXEEV, et al.
Published: (2016-12-01)

Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib
by: Fiala O, et al.
Published: (2021-05-01)

Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib
by: Keyvanjah Kiana, et al.
Published: (2012-08-01)

Targeted Therapy for Renal Cell Carcinoma: a Prospective study
by: Robin Joshi, et al.
Published: (2015-06-01)

Sustained systemic response paralleled with ovarian metastasis progression by sunitinib in metastatic renal cell carcinoma: Is this an anti-angiogenic potentiation of cancer?
by: Uttam K Mete, et al.
Published: (2015-01-01)

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
by: Yi-Ling Ko, et al.
Published: (2020-04-01)

Inhibition of retinopathy of prematurity in rat by intravitreal injection of sorafenib
by: Li-Li Tian, et al.
Published: (2014-04-01)

Individual approach in choosing second-line targeted therapy for metastatic renal cell carcinoma
by: B. Ya. Alekseev, et al.
Published: (2018-07-01)

Sunitinib induced nephrotic syndrome and thrombotic microangiopathy
by: P K Jha, et al.
Published: (2013-01-01)

Sorafenib-induced pemphigus vulgaris
by: Ajay Deshpande
Published: (2016-01-01)

Current Status and Future Direction of Multi-targeted Drugs  in the Era of Personalized Therapy —Overview of Advances in Multi-targeted Therapy in Non-small Cell Lung Cancer
by: Caicun ZHOU
Published: (2011-11-01)

Transformation of Nonfunctioning Pancreatic Neuroendocrine Carcinoma Cells into Insulin Producing Cells after Treatment with Sunitinib
by: Jung Hun Ohn, et al.
Published: (2013-06-01)

Heart Failure as First Sign of Development of Cardiac Metastases in a Patient with Diagnosis of Papillary Thyroid Carcinoma on Treatment with Tyrosine-Kinase Inhibitors: Differential Diagnoses and Clinical Management
by: Gema Bruixola, et al.
Published: (2014-08-01)

Pharmacokinetic/Pharmacodynamic Analysis of a Hemodialyzed Patient Treated with 25 mg of Sunitinib
by: Satoshi Noda, et al.
Published: (2012-11-01)

Osteonecrosis of the jaws in patient received bisphosphonates and sunitinib separately: A case report
by: Farzaneh Ashrafi, et al.
Published: (2017-01-01)

Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients
by: Çetin Ordu, et al.
Published: (2016-06-01)

Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results
by: Gaetano Facchini, et al.
Published: (2019-08-01)

Sunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule
by: Antonello Di Paolo, et al.
Published: (2017-08-01)

The role of sunitinib in the therapy of metastatic renal cell carcinoma
by: I. G. Rusakov, et al.
Published: (2020-07-01)

Optimization of sequential targeted therapy
by: B. Ya. Alekseev, et al.
Published: (2016-09-01)

Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma
by: Revati Sharma, et al.
Published: (2021-06-01)

Impact of Sunitinib on Human Thyroid Cancer Cells
by: Jirka Grosse, et al.
Published: (2013-07-01)